C. Dinwiddie, MSN, RN, FNP, CNN
David B. Van Wyck, MD
This satellite symposium
is sponsored by an unrestricted educational grant
from American Regent Laboratories, Inc. This activity
has been planned and produced in accordance with
CE guidelines and policies. From a CE symposium
held on October 17, 2004 at the American Nephrology
Nurses' Association (ANNA) Fall Meeting in New
Orleans, LA. This symposium was approved
by ANNA. It was not part of the official ANNA
This activity has been awarded 1.5 contact hours by
the American Nephrology Nurses Association (ANNA) which
is accredited as a provider and approver of continuing
education in nursing by the American Nurses Credentialing
Center-Commission on Accreditation (ANCC-COA).
After participating in this program, the participant should be able to:
Posting Date: January,
CE Credit Eligible
CE Credit Hours/Completion Time: 1.5
Target Audiences: Nurses, nurse practitioners, and other healthcare professionals who treat and manage patients with CKD.
Method of participation: Listen to the talk, read the PubMed
abstracts linked to data slides and talk references, take the post-test, read
the linked abstracts in the post-test answer feedback material.
- Describe the benefits of anemia management in chronic kidney disease (CKD).
- Outline the results of a U.S. clinical trial of iron sucrose and erythropoietin in the treatment of anemia in CKD.
- Appraise the characteristics of available parenteral iron products.
- Explain the critical role of the nephrology nurse in anemia management.
Speaker is a member of the Speakers Bureau
for American Regent Laboratories Inc.
| SPEAKER DISCLOSURE STATEMENT:
The CE policy and disclosure statements of the American Nephrology Nurses' Association
are given in detail on the Symposium
Home Page. The CE policy statements of HDCN are
| ANNA and HDCN CE POLICY